What's the Problem?

Many skin diseases are due to disorders in our immune system, notably psoriasis, vitiligo and atopic dermatitis, which affect more than 600 million people worldwide. In addition to conventional drug treatments, in recent years biological treatments with monoclonal antibodies have emerged for severe cases of these pathologies, showing very good efficacy. However, they are expensive and are not suitable for cream formulations because they are unstable molecules and too large to penetrate the skin’s layers. Furthermore, due to their systemic administration, they increase the appearance of adverse effects, lowering the defenses of patients and making it impossible to use it in people with a previous disease.

How are they Solving it?

Nanogrow is creating antibody-based biologics that can be formulated into creams. To achieve this, they use nanoantibodies: proteins derived from camelids, 10 times smaller than monoclonal ones, and with a much simpler, more robust and stable structure. This makes them resistant to topical formulations and therefore they can be applied directly on the lesion area, avoiding side effects. Thanks to their small size, they are able to penetrate the skin’s layers, neutralizing disease causing molecules. The key to their technological proposal is based on a novel nanobody development platform that allows them to rationally select ideal candidates for each application. In addition, they have the potential to bind these nanobodies to other molecules that can synergize their activity.

Go to their website

Next Startup

Nanotransfer

Go back to portfolio